Graves’ Hastalığına Sahip Olgularda Tiroid Maligniteleri
Amaç: Graves’ hastalığı otoimmün bir tiroid hastalığıdır. Eş zamanlı primer tiroid maligniteleri ile Graves’ hastalığı birlikteliği, giderek artan bir sıklıkta bildirilmektedir. Çalışmanın amacı laboratuarımızda incelenen Graves’ hastalığına sahip olguların tiroidektomi materyallerinde tiroid malignitesi sıklığını araştırmaktır. Yöntemler: 2010-2016 yılları arasında Recep Tayyip Erdoğan Üniversitesi Eğitim ve Araştırma Hastanesi Patoloji Laboratuarı’na Graves’ hastalığı nedeni ile gönderilen kırk (40) adet tiroidektomi materyaline ait preparat örnekleri yeniden incelendi. Bulgular: Kırk adet tiroidektomi materyalinin 11 (%27,5) tanesinde malignite saptandı. Malignitelerin tümü papiller karsinomdu. Makroskopik ya da mikroskopik olarak nodüle sahip Graves hastalıklı olgularda malignite sıklığı, nodülü olmayan gruba göre daha yüksek bulundu (p<0.05). Sonuç: Literatür ile uyumlu olarak, bu çalışmada da, Graves’ hastalığında nodül varlığının malignite riskini artırdığı gösterilmiştir. Nodüle sahip Graves’ hastaları klinik, radyolojik ve patolojik olarak dikkatli araştırılmalıdır
Thyroid Malignancies In Patients With Graves Disease
Objective: Graves’ disease is an autoimmune thyroid disorder. Concurrent Graves’ disease with primary thyroid malignancies has been reported at an increasing frequency. The aim of this study is to investigate the prevalence of primary thyroid malignancies among thyroidectomy specimens with Graves’ disease examined in our department. Methods: The slides of forty patients, which underwent thyroidectomy due to Graves’ disease, were reevaluated in between 2010 to 2016. Results: 11 of 40 thyroidectomy specimens (27.5%) had primary thyroid malignancy. All malignancies were papillary carcinoma. The prevalence of malignancy was significantly higher in cases of Graves’ disease with macroscopic or microscopic nodule than in Graves’ patients without nodule (p<0.05). Conclusion: This study also showed that the Graves’ disease with nodule had more risk of thyroid malignancy. The patients with concurrent Graves’ disease and thyroid nodule should be carefully examined clinically, radiological, and pathologically for thyroid cancer.
___
- 1. Menconi F, Marcocci C, Marino M. Diagnosis and classification
of Graves’ disease. Autoimmun Rev. 2014;13:398-402.
- 2. Cantalamessa L, Baldini M, Orsatti A, et al. Thyroid nodules
in Graves disease and the risk of thyroid carcinoma. Arch
Intern Med. 1999;159:1705-8.
- 3. Erbil Y, Barbaros U, Ozbey N, et al. Graves’ disease, with
and without nodules, and the risk of thyroid carcinoma. J
Laryngol Otol. 2008;122:291-5.
- 4. Tam AA, Kaya C, Kilic FB, et al. Thyroid nodules and thyroid
cancer in Graves’ disease. Arq Bras Endocrinol Metabol.
2014;58:933-8.
- 5. Boutzios G, Vasileiadis I, Zapanti E et al. Higher incidence
of tall cell variant of papillary thyroid carcinoma in Graves’
Disease. Thyroid. 2014;24:347-54.
- 6. Chen YK, Lin CL, Chang YJ, et al. Cancer risk in patients
with Graves’ disease: a nationwide cohort study. Thyroid.
2013;23:879-84.
- 7. Ergin AB, Saralaya S, Olansky L. Incidental papillary thyroid
carcinoma: clinical characteristics and prognostic factors
among patients with Graves’ disease and euthyroid
goiter, Cleveland Clinic experience. Am J Otolaryngol.
2014;35:784-90.
- 8. Gerenova J, Buysschaert M, de Burbure CY, Daumerie C.
Prevalence of thyroid cancer in Graves’ disease: a retrospective
study of a cohort of 103 patients treated surgically.
European Journal of Internal Medicine. 2003;14:321-5.
- 9. Lee J, Nam KH, Chung WY, et al. Clinicopathologic features
and treatment outcomes in differentiated thyroid carcinoma
patients with concurrent Graves’ disease. J Korean Med
Sci. 2008;23:796-801.
- 10. Phitayakorn R, McHenry CR. Incidental thyroid carcinoma
in patients with Graves’ disease. Am J Surg. 2008;195:292-
7; discussion 7.
- 11. Ren M, Wu MC, Shang CZ, et al. Predictive factors of thyroid
cancer in patients with Graves’ disease. World J Surg.
2014;38:80-7.
- 12. Staniforth JU, Erdirimanne S, Eslick GD. Thyroid carcinoma
in Graves’ disease: A meta-analysis. Int J Surg.
2016;27:118-25.
- 13. Tamatea JA, Tu’akoi K, Conaglen JV, et al. Thyroid cancer
in Graves’ disease: is surgery the best treatment for Graves’
disease? ANZ J Surg. 2014;84:231-4.
- 14. Wei S, Baloch ZW, LiVolsi VA. Thyroid carcinoma in patients
with Graves’ disease: an institutional experience. Endocr
Pathol. 2015;26:48-53.
- 15. LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid:
view, biases, and experiences. Adv Anat Pathol.
2004;11:279-87.
- 16. Harach HR, Franssila KO, Wasenius VM. Occult papillary
carcinoma of the thyroid. A “normal” finding in Finland. A
systematic autopsy study. Cancer. 1985;56:531-8.
- 17. Bradly DP, Reddy V, Prinz RA, Gattuso P. Incidental papillary
carcinoma in patients treated surgically for benign thyroid
diseases. Surgery. 2009;146:1099-104.
- 18. Mishra A, Mishra SK. Thyroid nodules in Graves’ disease:
implications in an endemically iodine deficient area. J Postgrad
Med. 2001;47:244-7.
- 19. Pellegriti G, Mannarino C, Russo M, et al. Increased mortality
in patients with differentiated thyroid cancer associated
with Graves’ disease. J Clin Endocrinol Metab.
2013;98:1014-21.
- 20. Preece J, Grodski S, Yeung M, et al. Thyrotoxicosis does
not protect against incidental papillary thyroid cancer. Surgery.
2014;156:1153-6.
- 21. Senyurek Giles Y, Tunca F, Boztepe H, et al. The risk factors
for malignancy in surgically treated patients for Graves’
disease, toxic multinodular goiter, and toxic adenoma. Surgery.
2008;144:1028-36; discussion 36-7.
- 22. Smith JJ, Chen X, Schneider DF, et al. Cancer after thyroidectomy:
a multi-institutional experience with 1,523
patients. J Am Coll Surg. 2013;216:571-7; discussion 7-9.
- 23. Taşkesen F, Uslukaya Ö, Kuzu H, et al. Coexistence of
hyperthyroidism and thyroid cancer. Dicle Tıp Dergisi.
2014;41:364-7.
- 24. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM.
The thyrotropin (TSH) receptor: interaction with TSH and
autoantibodies. Endocr Rev. 1998;19:673-716.
- 25. Belfiore A, Garofalo MR, Giuffrida D, et al. Increased aggressiveness
of thyroid cancer in patients with Graves’ disease.
J Clin Endocrinol Metab. 1990;70:830-5.
- 26. Karagülle E, Türk E, Ayvazoğlu Soy E, et al. Bir merkezde
tiroid papiller mikrokarsinom görülme sıklığı ve ameliyat
öncesi tetkiklerin tanısal değeri. Diyaliz Transplantasyon
ve Yanık. 2009;20:22-8.
- 27. Kim SH, Kim HY, Jung KY, et al. Anaplastic thyroid carcinoma
following radioactive iodine therapy for graves’ disease.
Endocrinol Metab (Seoul). 2013;28:61-4.
- 28. Meng ZW, Zhang YJ, Li W, et al. Relapse of hyperthyroidism
after hemithyroidectomy in concurrent medullary
thyroid cancer and Graves’ disease. Bratisl Lek Listy.
2013;114:544-6.
- 29. Baloch Z, LiVolsi VA, Tondon R. Aggressive variants of
follicular cell derived thyroid carcinoma; the so called ‘real
thyroid carcinomas’. J Clin Pathol. 2013;66:733-43.
- 30. Chai EZ, Siveen KS, Shanmugam MK, et al. Analysis of
the intricate relationship between chronic inflammation and
cancer. Biochem J. 2015;468:1-15.
- 31. Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s
thyroiditis a risk factor for papillary thyroid cancer? J Surg
Res. 2008;150:49-52.
- 32. Chui MH, Cassol CA, Asa SL, Mete O. Follicular epithelial
dysplasia of the thyroid: morphological and immunohistochemical
characterization of a putative preneoplastic lesion
to papillary thyroid carcinoma in chronic lymphocytic thyroiditis.
Virchows Arch. 2013;462:557-63.
- 33. Montone KT, Baloch ZW, LiVolsi VA. The thyroid Hurthle
(oncocytic) cell and its associated pathologic conditions: a
surgical pathology and cytopathology review. Arch Pathol
Lab Med. 2008;132:1241-50.
- 34. Guth S, Theune U, Aberle J, et al. Very high prevalence of
thyroid nodules detected by high frequency (13 MHz) ultrasound
examination. Eur J Clin Invest. 2009;39:699-706.
- 35. Anderson SR, Mandel S, LiVolsi VA, et al. Can cytomorphology
differentiate between benign nodules and tumors
arising in Graves’ disease? Diagnostic Cytopathology.
2004;31:64-7.